1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Roche, Chugai Weigh In As Tocilizumab Biosimilars Fail To Hit The Mark In Q3

Pair Of Actemra Biosimilars Available In US; Fresenius Kabi Bags Reimbursement Boost

 
• By Dean Rudge

While Roche admits that an acceleration of biosimilar competition to its blockbuster IL-6 inhibitor Actemra/RoActemra is anticipated in the final three months of the year, the Swiss originator has been surprised by the lack of challenge to its franchise so far.

China ADC competition
• Source: Shutterstock

Biosimilars to Roche’s Actemra/RoActemra (tocilizumab) in the US and Europe have not hit as hard as expected, the Swiss originator has outlined.

Fresenius Kabi recently stepped up marketing of its Tyenne (tocilizumab-aazg) rival to Actemra in the US, introducing the country’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By Dave Wallace

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By Dave Wallace

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By Dave Wallace

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

Biocon Biologics ‘Strategically’ Expands Enbrel Biosimilar With A Launch In Australia

 
• By Urtė Fultinavičiūtė

After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).

More from Generics Bulletin

‘By Most Measures A Failure’: Ten Years On From Teva-Actavis

 
• By Dean Rudge

A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By Dave Wallace

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By Dave Wallace

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.